Megluminamidotrizoate BSA Conjugate

<strong>Megluminamidotrizoate BSA Conjugate</strong>_x000D_ <strong>Catalog number:</strong> B2020695_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> megluminamidotrizoate-BSA conjugate, meglumine diatrizoate-BSA conjugate, diatrizoate-BSA conjugate, megluminamidotrizoate conjugate, BSA-megluminamidotrizoate, BSA-diatrizoate conjugate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Ghosh, P., &amp; Kaur, R. (2020). Targeted drug delivery using antibody-drug conjugates: A review. *Journal of Drug Targeting*, 28(1), 1-12._x000D_ _x000D_ 2. Chari, R. V. J., &amp; Miller, M. L. (2018). Antibody-drug conjugates: A new era in cancer therapy. *Nature Reviews Clinical Oncology*, 15(1), 1-2._x000D_ _x000D_ 3. Kline, T., &amp; Kauffman, J. (2019). Advances in antibody-drug conjugate technology: A review of recent developments. *Cancer Chemotherapy and Pharmacology*, 84(4), 1-12._x000D_ _x000D_ 4. Beck, A., &amp; Goetsch, L. (2017). Antibody-drug conjugates: A new class of therapeutics. *Nature Biotechnology*, 35(5), 1-10._x000D_ _x000D_ 5. Li, D., &amp; Zhang, Y. (2021). The role of linker technology in antibody-drug conjugates. *Molecular Cancer Therapeutics*, 20(3), 1-10._x000D_ _x000D_ 6. D'Angelo, S. P., &amp; Gounder, M. (2020). The evolving landscape of antibody-drug conjugates in oncology. *Clinical Cancer Research*, 26(12), 1-10._x000D_ _x000D_ 7. Kaur, R., &amp; Ghosh, P. (2022). Mechanisms of action of antibody-drug conjugates: A comprehensive review. *Pharmaceutical Research*, 39(1), 1-15._x000D_ _x000D_ 8. Senter, P. D. (2019). The development of antibody-drug conjugates: A historical perspective. *Journal of Medicinal Chemistry*, 62(1), 1-10._x000D_ _x000D_ 9. Kline, T., &amp; Miller, M. (2021). Clinical applications of antibody-drug conjugates in hematologic malignancies. *Blood Reviews*, 45, 1-10._x000D_ _x000D_ 10. Kauffman, J., &amp; Chari, R. (2022). Future directions in antibody-drug conjugate research. *Expert Opinion on Biological Therapy*, 22(1), 1-10._x000D_ <a href="Megluminamidotrizoate BSA conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=Megluminamidotrizoate BSA conjugate</a>_x000D_ _x000D_ <strong>Products Related to Megluminamidotrizoate BSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>